Back to Record

Assessing the impact of a safe and equitable biosimilar policy in the United States :
hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, May 2, 2007.

APA Citation

United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. (2008). Assessing the impact of a safe and equitable biosimilar policy in the United States: hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, May 2, 2007. Washington: U.S. G.P.O. .

MLA Citation

United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. Assessing the Impact of a Safe And Equitable Biosimilar Policy In the United States: Hearing Before the Subcommittee On Health of the Committee On Energy And Commerce, House of Representatives, One Hundred Tenth Congress, First Session, May 2, 2007. Washington: U.S. G.P.O. , 2008.

Warning: These citations may not always be complete (especially for serials).

Functional cookies

Statistics cookies

Marketing cookies

Assessing the impact of a safe and equitable biosimilar policy in the United States : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, May 2, 2007.

APA Citation

MLA Citation

Assessing the impact of a safe and equitable biosimilar policy in the United States :
hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, May 2, 2007.